linjc16/ctgov huggingface dataset:
Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a non-drug intensive program can help improve control of type 2 diabetes mellitus.

Detailed Description
-----------------
This study is based on the creation of two groups of patients with type 2 diabetes mellitus over a period of six months . In one of the groups an intensive program be developed through : group medical consultations , workshops , informative talks,  expert patient  telephone inquiries .. etc. Meanwhile , the control group that will be followed in the consultations as usual. We will make a determination of HbA1c at 3 months and 6 months later to assess whether there are significant differences between the two groups .

Official Title
-----------------
Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus With Poor Control of Their Disease

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Behavioral: Lifestyle counseling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with type 2 diabetes mellitus with poor control of their disease. No changes have been made in pharmacological previous 3 months. Exclusion Criteria: Changes in their drug treatment in the past 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lifestyle counseling<br>In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions. | Behavioral: Lifestyle counseling<br>* Group medical visits Telephone medical consultations Expert patient Training workshops<br>|
| No Intervention: Normal group<br>In this group will be controlled as usual in the consultations. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | 6 months |
Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
This is double blind randomized controlled trial on the statins effects on serum IgG, IgA and IgM level in chronic hemodialysis patients in Bandarabbas

Detailed Description
-----------------
This study is a randomized controlled trial of statins effect on serum IgG, IgA and IgM level on chronic hemodialysis patients in Bandarabbas. The study is carried out in Hormozgan, Iran. Seventy four patient were randomized either to receive atorvastatin in addition of usual treatment or not. The primary outcomes were serum IgG,IgA and IgM level. The secondary outcome was drug side effects.

Official Title
-----------------
Study of Statins' Effect on Serum IgG, IgA Ang IgM Level in Chronic Hemodialysis Patients

Conditions
-----------------
Chronic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Lipitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All chronic hemodialysis patients attending Shahid Mohammadi hospital during the study period Accepting to participate in the study Exclusion Criteria: Refusing to participate in the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lipitor<br>atorvastatin 20mg daily | Drug: Lipitor<br>* Atorvastatin 20mg daily for 6 months<br>* Other names: atorvastatin, statins;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum IgG, IgA and IgM level |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug side effects |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Statin
PET-CT in AML for Detection of Extramedullary AML Manifestations

Study Overview
=================
Brief Summary
-----------------
Myeloid Sarcoma (or granulocytic Sarcoma or Chloroma) is well defined by the WHO. However, there are currently no data about the prevalence, sites of occurence and thr prognostic value for patients with AML with this finding. Information about this condition is based on retrospective analyses since there have been no studies trying to define the role of myeloid sarcoma in AML so far. This observational trial will include adult patients with newly diagnosed and relapsed AML in order to perform 18FDG-PET-CT imaging prior to induction chemotherapy. Furthermore, a second 18FDG-PET-CT will be performed after induction chemotherapy to define the responsiveness of these tumors to chemotherapy. The primary endpoint of this study is the prevalence of 18FDG-PET-CT positive extramedullary AML manifestations (myeloid sarcoma) in patients with newly diagnosed or relapsed AML.

Official Title
-----------------
PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations

Conditions
-----------------
Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with newly diagnosed or relapsed AML AML FAB M0-2, M4-7 Signed informed consent after patient information Male and female patients with AML age 18-80 18FDG-PET-CT is available within a period of 5 days after diagnosis of AML Exclusion Criteria: AML FAB M3 (Promyelocytic Leukemia) lacking willingness to cooperate pregnancy or insufficient contraception 18FDG-PET-CT is not available within a period of 5 days after diagnosis of AML Medical condition of the patients requires an immediated start of chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute myeloid Leukemia, Myeloid Sarcoma, Extramedullary Acute myeloid Leukemia, 18FDG-PET-CT
Cervical Multifidus Muscle Function

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the relationship between cervical multifidi thickness, cervical spine proprioception and possible reflex activation of cervical multifidi through stimulation of joint mechanoreceptors. Cervical mechanoreceptors will be activated with an innocuous, nonspecific stimulation. Participants will have cervical spine proprioception assessed through joint position sense testing. The multifidus muscle thickness and activation state is to be assessed by sonography. These measures are done pre & post to the innocuous stimulation. There is no specific hypothesis.

Conditions
-----------------
Proprioception, Muscle Activation

Intervention / Treatment
-----------------
* Other: Nonspecific, Innocuous, Mechanoreceptor Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Logan student, staff, or faculty, ages 18 - 30 years Exclusion Criteria: Fractures Tumors Dislocations Myopathies Signs and/or symptoms of neuromotor disorders Consumption of prescription drugs that affect the nervous system Recent cervical spine injuries or surgeries Pain Manipulative therapy within the preceding 7 days Neck pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>This is a repeated measures study. All participants experience the same conditions. | Other: Nonspecific, Innocuous, Mechanoreceptor Stimulation<br>* A custom device will be used to provide light manual cervical traction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sonographic measurement of multifitus thickness |  | pre - post | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cervical spine repositioning error |  | pre - post |
The Promus Element Rewards Study

Study Overview
=================
Brief Summary
-----------------
This study is being done to study stent deformation on persons with de novo coronary lesions to determine how much deformation takes place and how often. The information gathered from the group that receives the Promus element stent will be compared to other groups that receive other contemporary drug eluting stents.

Official Title
-----------------
The Promus Element Rewards Study

Conditions
-----------------
Coronary Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, male or female, 18 years or older; Patients with de-novo coronary lesions and slated to receive a Promus Element stent; Patients who are slated to undergo IVUS after stent deployment during implantation procedure Exclusion Criteria: Patients receiving more than one drug-eluting stent within the same lesion during implantation procedure; Patients with in-stent restenosis; Patients who had IVUS imaging attained with manual pullback.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cypher<br>100 patients who have received a Cypher stent during their coronary intervention | |
| Taxus Express<br>100 patients who have received a Taxus Express stent during their coronary intervention | |
| Endeavor<br>100 patients who have received an Endeavor stent during their coronary intervention | |
| Promus/Xience V<br>100 patients who have received a Promus/Xience V stent during their coronary intervention | |
| Promus Element<br>100 patients who have received a Taxus Element stent during their coronary intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stent length | The primary endpoint of this study will be to assess the overall change in stent length post deployment by intravascualar ultrasound (IVUS) between the 5 stent groups. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IVUS stent length | The secondary endpoints of this analysis will be to detect the occurrence of a 10% change in stent length by IVUS as compared to the labeled stent length. | 1 day |
Autonomous Robotics for Transcatheter Cardiac Procedures

Study Overview
=================
Brief Summary
-----------------
Cardiovascular diseases represent the most common cause of death worldwide. Percutaneous approaches with intravascular catheters are pivotal, since they allow to treat patients with high perioperative risks. However, catheter-based treatments require steep learning curves and are characterized by poor ergonomics and exposure to damaging radiation. ARTERY will offer a radiation-free approach based on shared-autonomy robotic catheters, with increased user engagement and easy interaction. Intraprocedural three-dimensional echocardiography as well as computed tomography images obtained during usual clinical practice will provide artificial intelligence algorithms that will turn catheter navigation to a simple task. Optical and electromagnetic sensing techniques will ensure a superior view upon the cardiovascular anatomy and will guide the autonomous catheter upon the interventionist supervision, who will be able to take over control at any instant.

Official Title
-----------------
Autonomous Robotics for Transcatheter dEliveRy sYstems

Conditions
-----------------
Mitral Valve Disease, Heart Valve Diseases, Structural Heart Abnormality

Intervention / Treatment
-----------------
* Procedure: Percutaneous cardiac procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients patients admitted to hospital undergoing percutaneous cardiac procedure patients able to give informed consent Exclusion Criteria: age <18 years refuse to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Percutaneous cardiac procedures<br>Patients undergoing percutaneous cardiac procedures | Procedure: Percutaneous cardiac procedure<br>* Collection and analysis of intraprocedural information to provide artificial intelligence algorithms<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of key procedural elements that will benefit from the technological developments introduced by ARTERY by collecting intraprocedural images | Number of patients undergoing percutaneous cardiac procedures | Intraoperative period |
Treatment of Hypertension in Primary Care in Spain

Study Overview
=================
Brief Summary
-----------------
Non-interventional,observational and retrospective study assessing the therapeutic and diagnostic attitude followed in primary care for a hypertensive patient depending on his degree of blood pressure control.

Official Title
-----------------
Treatment of Hypertension in Primary Care in Spain

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of primary hypertension and/or treated for hypertension for one year or more Clinical data of blood pressure measures for the last 12+/- 2 months before inclusion. Exclusion Criteria: Secondary Hypertension Physical or psychological impairment for the understanding of the information to be given to the patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study | |
| 2<br>Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study. | |
| 3<br>Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study | |
| 4<br>Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study | |
| 5<br>Blood Pressure well controlled in the previous year independently of the level of control at the inclusion. | |
| 6<br>Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Therapeutic and diagnostic attitude followed in primary care for a hypertensive patient depending on his degree of blood pressure control. |  | 1 Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation in the Percentage of patients with blood pressure controlled and not controlled during a year of follow-up. |  | 1 Year | 
| Clinical profile and cardiovascular risk. |  | 1 Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Therapeutic diagnostic attitude, Blood pressure
Transthoracic Shear-wave Ultrasound Elastography

Study Overview
=================
Brief Summary
-----------------
This study aims to provide the information of tissue elasticity in different etiologies of pulmonary lesions and to validate the predictive value of shear-wave elastography in differentiating benign pulmonary lesions from malignant lesions.

Official Title
-----------------
Application of Transthoracic Shear-wave Ultrasound Elastography in the Diagnosis of Pulmonary Lesions

Conditions
-----------------
Elasticity Imaging Techniques

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: (1) Retrospective cohort from Jan 2016 to Dec 2017 (2) Patients with radiographic evidence of pulmonary tumors Exclusion criteria: (1) age < 20 y/o (2) patients who can't hold their breath for 5 seconds

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Application of Transthoracic Shear-wave Ultrasound Elastography in the Diagnosis of Pulmonary Lesions | to provide the information of tissue elasticity in different etiologies of pulmonary lesions and to validate the predictive value of shear-wave elastography in differentiating benign pulmonary lesions from malignant lesions | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chest ultrasound,Lung tumor
The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment

Study Overview
=================
Brief Summary
-----------------
To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification in patients on coumadin and antiaggregant treatments. Design: Consecutive prospective study.

Detailed Description
-----------------
To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification technique in patients on coumadin and antiaggregant treatment Design: Consecutive prospective study.

Official Title
-----------------
The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment

Conditions
-----------------
Efficacy, Complications

Intervention / Treatment
-----------------
* Procedure: cataract surgery with phacoemulsification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who give informed consent to participate in the study Exclusion Criteria: single eye complicated cataract
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: A<br>patients under coumadin and antiaggregants operated by phacoemulsification | Procedure: cataract surgery with phacoemulsification<br>* removal of cataract with phacoemulsification technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety and efficacy of cataract surgery with phacoemulsification under coumadin and antiaggregant treatment |  | 3.5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| other complications |  | 3.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cataract, phacoemulsification, coumadin, antiaggregants
Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

Study Overview
=================
Brief Summary
-----------------
To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women. To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).

Detailed Description
-----------------
Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

Official Title
-----------------
Clinical Professor of Shanghai Tongji Hospital

Conditions
-----------------
HDFN

Intervention / Treatment
-----------------
* Other: zimin Lu,Guo Sa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: blood samples of pregnant couples,gender/nation/region is unlimited. Exclusion Criteria: adipose or hemolytic samples,overdue samples,unidentified samples

Ages Eligible for Study
-----------------
Minimum Age: 12 Weeks
Maximum Age: 38 Weeks

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: zimin Lu,Guo Sa|chengzhong Liu|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |